Atypical Depression Clinical Trial
Official title:
A Study of Modafinil for Atypical Depression
The purposes of the study are to: 1) evaluate the short-term efficacy and safety of modafinil in atypical depression; and 2) to evaluate the efficacy of modafinil in preventing relapse of atypical depression. The hypothesis is that modafinil is safe and effective in the treatment of atypical depression.
This study on the safety and efficacy of modafinil on atypical depression has an initial 12-week open label treatment period with modafinil that is followed by a 12-week double-blind, randomized parallel treatment period with either modafinil or matching placebo. Patients who demonstrate at least minimal improvement after 12 weeks are randomly assigned to either continuing treatment at their current dose or switched to matching placebo for 12 weeks. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00610506 -
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
|
Phase 3 | |
| Completed |
NCT00296699 -
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression
|
Phase 4 | |
| Completed |
NCT00861978 -
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
|
Phase 3 | |
| Completed |
NCT00477854 -
Effects of Chromium Picolinate on Food Intake
|
N/A |